These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 39109213)

  • 1. Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study.
    Cai J; Wang H; Ye X; Lu S; Tan Z; Li Z; Lin D; Qian J; Lu X; Wan J; Wang J; Ai J; Pu Y; Qu L; Wang S
    Front Microbiol; 2024; 15():1428095. PubMed ID: 39109213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
    Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
    Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
    N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of baloxavir marboxil and oseltamivir for influenza in children: a real-world retrospective study in China.
    Ge X; Chen Y; Wu W; Lu J; Wang Y; Li Z
    Front Pediatr; 2024; 12():1418321. PubMed ID: 39135856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.
    Wagatsuma K; Saito R; Chon I; Phyu WW; Fujio K; Kawashima T; Sato I; Saito T; Minato M; Kodo N; Suzuki E; Ono Y; Masaki H; Shirahige Y; Kitano A; Hamabata H; Yuyang S; Jiaming L; Watanabe H
    Antiviral Res; 2022 May; 201():105310. PubMed ID: 35358601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China.
    Liao G; Xia M; Jiang Y; Chen H; Liao W; Peng J; Cai S
    Front Microbiol; 2023; 14():1292735. PubMed ID: 38088961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective observational study of the treatment of a nosocomial infection caused by oseltamivir-resistant influenza virus A with baloxavir marboxil.
    Fujita M; Matsumoto H; Inafuku Y; Toyama J; Fujita J
    Respir Investig; 2020 Sep; 58(5):403-408. PubMed ID: 32605828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.
    Li Y; Wang X; Liao Y; Zeng Y; Lin W; Zhuang W
    BMC Infect Dis; 2024 May; 24(1):446. PubMed ID: 38724914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of baloxavir marboxil on household transmission of influenza infection.
    Umemura T; Mutoh Y; Kawamura T; Saito M; Mizuno T; Ota A; Kozaki K; Yamada T; Ikeda Y; Ichihara T
    J Pharm Health Care Sci; 2020; 6():21. PubMed ID: 33014405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
    Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
    Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom.
    Kommandantvold SA; Lemenuel-Diot A; Skedgel C; Pitman R; Rouse P; Zaraket H; Zhou H; Blanchet Zumofen MH
    Expert Rev Pharmacoecon Outcomes Res; 2024 Oct; 24(8):953-966. PubMed ID: 38850520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir.
    Nezu K; Hayashida S; Nagano N; Udagawa S; Morioka I
    Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763660
    [No Abstract]   [Full Text] [Related]  

  • 13. The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system.
    Wei W; Huang L; Bai Y; Chang E; Liu J
    Front Pharmacol; 2024; 15():1391003. PubMed ID: 39050747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness of baloxavir marboxil against influenza in three seasons.
    Kakuya F; Okubo H; Fujiyasu H; Kurisawa MJ; Kinebuchi T
    Pediatr Int; 2022 Jan; 64(1):e15169. PubMed ID: 35790049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
    Fukao K; Noshi T; Yamamoto A; Kitano M; Ando Y; Noda T; Baba K; Matsumoto K; Higuchi N; Ikeda M; Shishido T; Naito A
    J Antimicrob Chemother; 2019 Mar; 74(3):654-662. PubMed ID: 30476172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials.
    Kuo YC; Lai CC; Wang YH; Chen CH; Wang CY
    J Microbiol Immunol Infect; 2021 Oct; 54(5):865-875. PubMed ID: 34020891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States.
    Kommandantvold SA; Chang SC; Surinach A; Yau V; Best JH; Zaraket H; Zhou H; Frimpter J; Blanchet Zumofen MH
    Infect Dis Ther; 2024 Sep; 13(9):2071-2087. PubMed ID: 39150658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
    Taieb V; Ikeoka H; Wojciechowski P; Jablonska K; Aballea S; Hill M; Hirotsu N
    Curr Med Res Opin; 2021 Feb; 37(2):225-244. PubMed ID: 33079575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
    Komeda T; Takazono T; Hosogaya N; Miyazaki T; Ogura E; Iwata S; Miyauchi H; Honda K; Fujiwara M; Ajisawa Y; Watanabe H; Kitanishi Y; Hara K; Mukae H
    Clin Infect Dis; 2021 Sep; 73(5):e1181-e1190. PubMed ID: 33354728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis.
    Shiraishi C; Kato H; Hagihara M; Asai N; Iwamoto T; Mikamo H
    J Infect Chemother; 2024 Mar; 30(3):242-249. PubMed ID: 37866622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.